Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Procainamide Articles

FDA backs Pfizer's dofetilide, launch slated for early 2000

11 October 1999

Warner-Lambert & King In $125M Deal

4 March 1998

Cordarone Gives Early Benefit In Out-Of-Hospital Setting

20 November 1997

Copley Will Plead Guilty To Criminal Charges

9 June 1997

Questions Raised Over Hoechst Drug Division Split

3 February 1997

Russian Drug Output Fails To Meet Demand

27 January 1997

Copley Pharmaceuticals ANDA For CV Drug Approved In USA

23 December 1996

P&U Launches First Atrial Fibrillation Drug In the USA

22 April 1996

NEW YORK STOCK COMMENT

19 February 1996

W-L's Procanbid Cleared In USA

12 February 1996

Corvert Effective For Arrhythmia, Says Panel

30 October 1995

FDA Panel Backs IV Cordarone Approval

31 October 1994

Probucol link to unstable heart behavior

1 June 1992

SOTALOL BEST, SAYS ARRHYTHMIA STUDY

27 April 1992

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Italy's pharma market slump set to continue, warns GlobalData
  • Pfizer to split-off remaining 80% interest in Zoetis
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Italy's pharma market slump set to continue, warns GlobalData
  • Pfizer to split-off remaining 80% interest in Zoetis

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS